Phase II study of anguidine in advanced breast cancer.

  title={Phase II study of anguidine in advanced breast cancer.},
  author={Hwee Yong Yap and William J. Murphy and Angela Distefano and George R. Blumenschein and Gerald Paul Bodey},
  journal={Cancer treatment reports},
  volume={63 5},
A phase II evaluation of anguidine was carried out in 30 patients with advanced refractory breast cancer. A dose of 5.0 mg/m2 daily for 5 days was explored. The main toxic effects were nausea and vomiting, fever and chills, hypotension, skin erythema, somnolence, confusion, and lethargy. Myelosuppression was minimal. Among these extensively pretreated… CONTINUE READING